|
1
|
Sporn MB and Liby KT: Nrf2 and cancer: The
good, the bad and the importance of context. Nat Rev Cancer.
12:564–571. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhao Q, Mao A, Yan J, Sun C, Di C, Zhou X,
Li H, Guo R and Zhang H: Downregulation of Nrf2 promotes
radiation-induced apoptosis through Nrf2 mediated Notch signaling
in non-small cell lung cancer cells. Int J Oncol. 48:765–773. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chen Z1, Ye X, Tang N, Shen S, Li Z, Niu
X, Lu S and Xu L: The histone acetylranseferase hMOF acetylates
Nrf2 and regulates anti-drug responses in human non-small cell lung
cancer. Br J Pharmacol. 171:3196–3211. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Biswas M and Chan JY: Role of Nrf1 in
antioxidant response element-mediated gene expression and beyond.
Toxicol Appl Pharmacol. 244:16–20. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Li SS, Chen ZY, Li J, Xu Z and Yang X:
Research progress of Keap1/Nrf2/ARE signaling pathway in central
nervous system diseases. Chinese Gen Pract. 3641–3644. 2014.
|
|
6
|
Namani A, Li Y, Wang XJ and Tang X:
Modulation of NRF2 signaling pathway by nuclear receptors:
Implications for cancer. Biochim Biophys Acta. 1843:1875–1885.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Arnold P, Mojumder D, Detoledo J, Lucius R
and Wilms H: Pathophys-iological processes in multiplesclerosis:
Focus on nu-clear factor erythroid-2-related factor 2 and emerging
pathways. Clin Pharmacol. 6:35–42. 2014.PubMed/NCBI
|
|
8
|
Mitsuishi Y, Taguchi K, Kawatani Y,
Shibata T, Nukiwa T, Aburatani H, Yamamoto M and Motohashi H: Nrf2
redirects glucose and glutamine into anabolic pathways in metabolic
reprogramming. Cancer Cell. 22:66–79. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kumar H, Kim IS, More SV, Kim BW and Choi
DK: Natural product-derived pharmacological modulators of Nrf2/ARE
pathway for chronic diseases. Nat Prod Rep. 31:109–139. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Homma S, Ishii Y, Morishima Y, Yamadori T,
Matsuno Y, Haraguchi N, Kikuchi N, Satoh H, Sakamoto T, Hizawa N,
et al: Nrf2 enhances cell proliferation and resistance to
anticancer drugs in human lung cancer. Clin Cancer Res.
15:3423–3432. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang P, Singh A, Yegnasubramanian S,
Esopi D, Kombairaju P, Bodas M, Wu H, Bova SG and Biswal S: Loss of
Kelch-like ECH-associated protein 1 function in prostate cancer
cells causes chemoresistance and radioresistance and promotes tumor
growth. Mol Cancer Ther. 9:336–346. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yang X, Wang D, Ma Y, Xu X, Zhu Z, Wang X,
Deng H, Li C, Chen M, Tong J, et al: Continuous activation of Nrf2
and its target antioxidant enzymes leads to arsenite-induced
malignant transformation of human bronchial epithelial cells.
Toxicol Appl Pharmacol. 289:231–239. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lubelska K, Milczarek M, Modzelewska K,
Krzysztoń-Russjan J, Fronczyk K and Wiktorska K: Interactions
between drugs and sulforaphane modulate the drug metabolism
enzymatic system. Pharmacol Rep. 64:1243–1252. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ji L, Li H, Gao P, Shang G, Zhang DD,
Zhang N and Jiang T: Nrf2 pathway regulates
multidrug-resistance-associated protein 1 in small cell lung
cancer. PLoS One. 8:e634042013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Son YO, Pratheeshkumar P, Roy RV, Hitron
JA, Wang L, Zhang Z and Shi X: Nrf2/p62 signaling in apoptosis
resistance and its Role in cadmium-induced carcinogenesis. J Biol
Chem. 289:28660–28675. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ma X, Zhang J, Liu S, Huang Y, Chen B and
Wang D: Nrf2 knockdown by shRNA inhibits tumor growth and increases
efficacy of chemotherapy in cervical cancer. Cancer Chemother
Pharmacol. 69:485–494. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lee D, Bae J, Kim YK, Gil M, Lee JY, Park
CS and Lee KJ: Inhibitory effects of berberine on
lipopolysaccharide-induced inducible nitric oxide synthase and the
high-mobility group box 1 release in macrophages. Biochem Biophys
Res Commun. 431:506–511. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cong ZX, Wang HD, Wang JW, Zhou Y, Pan H,
Zhang DD and Zhu L: ERK and PI3K signaling cascades induce Nrf2
activation and regulate cell viability partly through Nrf2 in human
glioblastoma cells. Oncol Rep. 30:715–716. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sun Z, Huang Z and Zhang DD:
Phosphorylation of Nrf2 at multiple sites by MAP kinases has a
limited contribution in modulating the Nrf2-dependent antioxidant
response. PLoS One. 4:e65882009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Levy S, Jaiswal AK and Forman HJ: The role
of c-Jun phosphorylation in EpRE activation of phase II genes. Free
Radic Biol Med. 47:1172–1179. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Abazeed ME, Adams DJ, Hurov KE, Tamayo P,
Creighton CJ, Sonkin D, Giacomelli AO, Du C, Fries DF, Wong KK, et
al: Integrative radiogenomic profiling of squamous cell lung
cancer. Cancer Res. 73:6289–6298. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yip PY: Phosphatidylinositol
3-kinase-AKT-mammalian target of rapamycin (PI3K-Akt-mTOR)
signaling pathway in non-small cell lung cancer. Transl Lung Cancer
Res. 4:165–176. 2015.PubMed/NCBI
|
|
23
|
Romero IL, McCormick A, McEwen KA, Park S,
Karrison T, Yamada SD, Pannain S and Lengyel E: Relationship of
type II diabetes and metformin use to ovarian cancer progression,
survival, and chemosensitivity. Obstet Gynecol. 119:61–67. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lai SW, Liao KF, Chen PC, Tsai PY, Hsieh
DP and Chen CC: Antidiabetes drugs correlate with decreased risk of
lung cancer: A population-based observation in Taiwan. Clin Lung
Cancer. 13:143–148. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kobayashi M, Kato K, Iwama H, Fujihara S,
Nishiyama N, Mimura S, Toyota Y, Nomura T, Nomura K, Tani J, et al:
Antitumor effect of metformin in esophageal cancer: In vitro study.
Int J Oncol. 42:517–524. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kato K, Gong J, Iwama H, Kitanaka A, Tani
J, Miyoshi H, Nomura K, Mimura S, Kobayashi M, Aritomo Y, et al:
The antidiabetic drug metformin inhibits gastric cancer cell
proliferation in vitro and in vivo. Mol Cancer Ther. 11:549–560.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Colquhoun AJ, Venier NA, Vandersluis AD,
Besla R, Sugar LM, Kiss A, Fleshner NE, Pollak M, Klotz LH and
Venkateswaran V: Metformin enhances the antiproliferative and
apoptotic effect of bicalutamide in prostate cancer. Prostate
Cancer Prostatic Dis. 15:346–352. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ashinuma H, Takiguchi Y, Kitazono S,
Kitazono-Saitoh M, Kitamura A, Chiba T, Tada Y, Kurosu K, Sakaida
E, Sekine I, et al: Antiproliferative action of metformin in human
lung cancer cell lines. Oncol Rep. 28:8–14. 2012.PubMed/NCBI
|
|
29
|
Koeck S, Amann A, Huber JM, Gamerith G,
Hilbe W and Zwierzina H: The impact of metformin and salinomycin on
transforming growth factor β-induced epithelial-to-mesenchymal
transition in non-small cell lung cancer cell lines. Oncol Lett.
11:2946–2952. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yue W, Yang CS, DiPaola RS and Tan XL:
Repurposing of metformin and aspirin by targeting AMPK-mTOR and
inflammation for pancreatic cancer prevention and treatment. Cancer
Prev Res (Phila). 7:388–397. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ferla R, Haspinger E and Surmacz E:
Metformin inhibits leptin-induced growth and migration of
glioblastoma cells. Oncol Lett. 4:1077–1081. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Liu B, Fan Z, Edgerton SM, Deng XS,
Alimova IN, Lind SE and Thor AD: Metformin induces unique
biological and molecular responses in triple negative breast cancer
cells. Cell Cycle. 8:2031–2040. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Vazquez-Martin A, Oliveras-Ferraros C and
Menendez JA: The antidiabetic drug metformin suppresses HER2
(erbB-2) oncoprotein overexpression via inhibition of the mTOR
effector p70S6K1 in human breast carcinoma cells. Cell Cycle.
8:88–96. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hanna RK, Zhou C, Malloy KM, Sun L, Zhong
Y, Gehrig PA and Bae-Jump VL: Metformin potentiates the effects of
paclitaxel in endometrial cancer cells through inhibition of cell
proliferation and modulation of the mTOR pathway. Gynecol Oncol.
125:458–469. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Rocha GZ, Dias MM, Ropelle ER,
Osório-Costa F, Rossato FA, Vercesi AE, Saad MJ and Carvalheira JB:
Metformin amplifies chemotherapy-induced AMPK activation and
antitumoral growth. Clin Cancer Res. 17:3993–4005. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Gotlieb WH, Saumet J, Beauchamp MC, Gu J,
Lau S, Pollak MN and Bruchim I: In vitro metformin anti-neoplastic
activity in epithelial ovarian cancer. Gynecol Oncol. 110:246–250.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yu C, Jiao Y, Xue J, Zhang Q, Yang H, Xing
L, Chen G, Wu J, Zhang S, Zhu W and Cao J: Metformin sensitizes
non-small cell lung cancer cells to an epigallocatechin-3-gallate
(EGCG) treatment by suppressing the Nrf2/HO-1 signaling pathway.
Int J Biol Sci. 13:1560–1569. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Rodenak-Kladniew B, Castro A, Stärkel P,
De Saeger C, de Bravo García M and Crespo R: Linalool induces cell
cycle arrest and apoptosis in HepG2 cells through oxidative stress
generation and modulation of Ras/MAPK and Akt/mTOR pathways. Life
Sci. 199:48–59. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kim SK, Yang JW, Kim MR, Roh SH, Kim HG,
Lee KY, Jeong HG and Kang KW: Increased expression of
Nrf2/ARE-dependent anti-oxidant proteins in tamoxifen-resistant
breast cancer cells. Free Radic Biol Med. 45:537–546. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Vollrath V, Wielandt AM, Iruretagoyena M
and Chianale J: Role of NrO in the regulation of the Mrp2 (ABCC2)
gene. Biochem J. 395:599–609. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Tang X, Wang H, Fan L, Wu X, Xin A, Ren H
and Wang XJ: Luteolin inhibits Nrf2 leading to negative regulation
of the Nrf2/ARE pathway and sensitization of human lung carcinoma
A549 cells to therapeutic drugs. Free Radic Biol Med. 50:1599–1609.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Hwang YP, Choi JH, Choi JM, Chung YC and
Jeong HG: Protective mechanisms of anthocyanins from purple sweet
potato against tert-butyl hydroperoxide-induced hepatotoxicity.
Food Chem Toxicol. 49:2081–2089. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Soeur J, Eilstein J, Léreaux G, Jones C
and Marrot L: Skin resistance to oxidative stress induced by
resveratrol: From Nrf2 activation to GSH biosynthesis. Free Radic
Biol Med. 78:213–223. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Meyer Zu, Schwabedissen HE, Grube M,
Heydrich B, Linnemann K, Fusch C, Kroemer HK and Jedlitschky G:
Expression, localization, and function of MRP5 (ABCC5), a
transporter for cyclic nucleotides, in human placenta and cultured
human trophoblasts: Effects of gestational age and cellular
differentiation. Am J Pathol. 166:39–48. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Lu BC, Li J, Yu WF, Zhang GZ, Wang HM and
Ma HM: Elevated expression of Nrf2 mediates multidrug resistance in
CD133+ head and neck squamous cell carcinoma stem cells.
Oncol Lett. 12:4333–4338. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Wang J, Liu X and Jiang W: Co-transfection
of MRP and bcl-2 antisense S-oligodeoxynucleotides reduces drug
resistance in cisplatin-resistant lung cancer cells. Chin Med J
(Engl). 113:957–960. 2000.PubMed/NCBI
|
|
48
|
Neubauer H, Stefanova M, Solomayer E,
Meisner C, Zwirner M, Wallwiener D and Fehm T: Predicting
resistance to platinum-containing chemotherapy with the ATP tumor
chemosensitivity assay in primary ovarian cancer. Anticancer Res.
28:949–955. 2008.PubMed/NCBI
|
|
49
|
Meijerman I, Beijnen JH and Schellens JH:
Combined action and regulation of phase II enzymes and multidrug
resistance proteins in multidrug resistance in cancer. Cancer Treat
Rev. 34:505–520. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Stein SC, Woods A, Jones NA, Davison MD
and Carling D: The regulation of AMP-activated protein kinase by
phosphorylation. Biochem J. 345:437–443. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Tsuji K, Kisu I, Banno K, Yanokura M, Ueki
A, Masuda K, Kobayashi Y, Yamagami W, Nomura H, Susumu N and Aoki
D: Metformin: A possible drug for treatment of endometrial cancer.
Open J Obstet Gynecol. 2:1–6. 2012. View Article : Google Scholar
|
|
52
|
Kato K, Ogura T, Kishimoto A, Minegishi Y,
Nakajima N, Miyazaki M and Esumi H: Critical roles of AMP-activated
protein kinase in constitutive tolerance of cancer cells to
nutrient deprivation and tumor formation. Oncogene. 21:6082–6090.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Rattan R, Graham RP, Maguire JL, Giri S
and Shridhar V: Metformin suppresses ovarian cancer growth and
metastasis with enhancement of cisplatin cytotoxicity in vivo.
Neoplasia. 13:483–491. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Krall EB, Wang B, Munoz DM, Ilic N,
Raghavan S, Niederst MJ, Yu K, Ruddy DA, Aguirre AJ, Kim JW, et al:
KEAP1 loss modulates sensitivity to kinase targeted therapy in lung
cancer. Elife. 6:pii: e18970. 2017. View Article : Google Scholar
|
|
55
|
Engelman JA, Luo J and Cantley LC: The
evolution of phosphatidylinositol 3-kinases as regulators of growth
and metabolism. Nat Rev Genet. 7:606–619. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Forbes SA, Bindal N, Bamford S, Cole C,
Kok CY, Beare D, Jia M, Shepherd R, Leung K, Menzies A, et al:
COSMIC: Mining complete cancer genomes in the catalogue of somatic
mutations in cancer. Nucleic Acids Res. 39:(Database Issue).
D945–D950. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Samatar AA and Poulikakos PI: Targeting
RAS-ERK signalling in cancer: Promises and challenges. Nat Rev Drug
Discov. 13:928–942. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Pilot-Storck F, Chopin E, Rual JF, Baudot
A, Dobrokhotov P, Robinson-Rechavi M, Brun C, Cusick ME, Hill DE,
Schaeffer L, et al: Interactome mapping of the phosphatidylinositol
3-kinase-mammalian target of rapamycin pathway identifies deformed
epidermal autoregulatory factor-1 as a new glycogen synthase
kinase-3 interactor. Mol Cell Proteomics. 9:1578–1593. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Aksamitiene E, Kiyatkin A and Kholodenko
BN: Cross-talk between mitogenic Ras/MAPK and survival PI3K/Akt
pathways: A fine balance. Biochem Soc Trans. 40:139–146. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Fruman DA and Rommel C: P13K and cancer:
Lessons, challenges and opportunities. Nat Rev Drug Discov.
13:140–156. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Steelman LS, Chappell WH, Abrams SL, Kempf
RC, Long J, Laidler P, Mijatovic S, Maksimovic-Ivanic D, Stivala F,
Mazzarino MC, et al: Roles of the Raf/MEK/ERK and
PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity
to therapy-implications for cancer and aging. Aging (Albany NY).
3:192–222. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Liu P, Cheng H, Roberts TM and Zhao JJ:
Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev
Drug Discov. 8:627–644. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Will M, Qin AC, Toy W, Yao Z,
Rodrik-Outmezguine V, Schneider C, Huang X, Monian P, Jiang X, de
Stanchina E, et al: Rapid induction of apoptosis by PI3K inhibitors
is dependent upon their transient inhibition of RAS-ERK signaling.
Cancer Discov. 4:334–347. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Chandarlapaty S, Sawai A, Scaltriti M,
Rodrik-Outmezguine V, Grbovic-Huezo O, Serra V, Majumder PK,
Baselga J and Rosen N: AKT inhibition relieves feedback suppression
of receptor tyrosine kinase expression and activity. Cancer Cell.
19:58–71. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
McCubrey JA, Steelman LS, Chappell WH,
Abrams SL, Franklin RA, Montalto G, Cervello M, Libra M, Candido S,
Malaponte G, et al: Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade
inhibitors: How mutations can result in therapy resistance and how
to overcome resistance. Oncotarget. 3:1068–1111. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Fritsch R, de Krijger I, Fritsch K, George
R, Reason B, Kumar MS, Diefenbacher M, Stamp G and Downward J: RAS
and RHO families of GTPases directly regulate distinct
phosphoinositide 3-kinase isoforms. Cell. 153:1050–1063. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Zhang HK, Xu TJ, Ju YH and Yu AM: PI3K/AKT
and MAPK/ERK pathways induce cell cycle arrest and apoptosis in
A549 cell through the regulation of FOXO1 transcription factor. J
China Med Univ. 908–911. 2012.
|
|
68
|
Tian Y, Wu K, Liu Q, Han N, Zhang L, Chu Q
and Chen Y: Modification of platinum sensitivity by KEAP1/NRF2
signals in non-small cell lung cancer. J Hematol Oncol. 9:832016.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Tian Y, Liu Q, He X, Yuan X, Chen Y, Chu Q
and Wu K: Emerging roles of Nrf2 signal in non-small cell lung
cancer. J Hematol Oncol. 9:142016. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Singer E, Judkins J, Salomonis N, Matlaf
L, Soteropoulos P, McAllister S and Soroceanu L: Reactive oxygen
species-mediated therapeutic response and resistance in
glioblastoma. Cell Death Dis. 6:e16012015. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Del Vecchio CA, Feng Y, Sokol ES, Tillman
EJ, Sanduja S, Reinhardt F and Gupta PB: De-differentiation confers
multidrug resistance via noncanonical PERK-Nrf2 signaling. PLoS
Biol. 12:e10019452014. View Article : Google Scholar : PubMed/NCBI
|
